ERK Inhibitor Compounds Targeting Raf/MEK/ERK Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new and novel therapeutic agents that can effectively target the frequently overexpressed and/or overactive Raf/MEK/ERK signaling pathway in cancerous tissues to treat various hyperproliferative disorders, including cancers such as melanoma, pancreatic cancer, and breast cancer, as well as conditions like pain and inflammation.
Innovation Solution
Development of specific compounds, such as those represented by Formulas I, II, III, IV, V, VI, VII, VIII, IX, and X, or their stereoisomers, tautomers, or pharmaceutically acceptable salts, which inhibit ERK protein kinase activity, thereby attenuating or eliminating ERK kinase activity in cells, and can be administered alone or in combination with other anti-hyperproliferative compounds to treat hyperproliferative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ERK inhibitors are used, then some cancer treatment effect is achieved, but therapeutic efficacy is insufficient and resistance develops
Solution Approach 1:
The patent modifies the chemical structure of ERK inhibitors by changing molecular parameters - introducing specific substituents (fluoro, chloro, bromo groups) and modifying the core scaffold (e.g., pyridine, pyrimidine rings) to enhance binding affinity and overcome resistance mechanisms, thereby improving therapeutic efficacy without sacrificing productivity
2Adaptability or versatility
If multiple kinase inhibitors are combined to target different pathways, then treatment coverage is improved, but drug complexity and interaction management become more difficult
Solution Approach 1:
The patent designs ERK inhibitors with broad-spectrum activity that can effectively target multiple cancer types and resistance mechanisms through a single compound class, reducing the need for complex multi-drug regimens while maintaining comprehensive treatment coverage across different pathological contexts
Data Source
AI summary
Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.